Responses
Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1382 Discovery of ALG-094103, a liver-targeted and orally bioavailable small molecule PD-L1 inhibitor for the treatment of liver cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.
